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Meta-Analysis and a Large Association Study Confirm
a Role for Calpain-10 Variation in Type 2 Diabetes
Susceptibility
To the Editor:
Variation in the calpain-10 gene (CAPN10 [MIM
605286]) was recently linked and associated with type
2 diabetes mellitus (T2DM) susceptibility (Horikawa et
al. 2000). The initial linkage of T2DM to chromosome
2 was found in a population of Mexican Americans from
Starr County, Texas (Hanis et al. 1996). Specific com-
binations of three intronic variants, designated “SNP-
43,” “SNP-19,” and “SNP-63,” that capture most of
the haplotype diversity at CAPN10 were associated with
a three-fold increased risk of T2DM in this population
and could account for the observed linkage (Horikawa
et al. 2000). Subsequent association and linkage studies
of these three polymorphisms in other populations have
produced conflicting results, with association being ob-
served in some populations (Baier et al. 2000 [Pima In-
dian]; Cassell et al. 2002 [South Indian]; Garant et al.
2002 [African American]; Malecki et al. 2002 [Polish];
Orho-Melander et al. 2002 [Finnish/Botnia]), but not
others (Evans et al. 2001 [British]; Hegele et al. 2001
[Oji-Cree Indians]; Tsai et al. 2001 [Samoan]; Xiang et
al. 2001 [Chinese]; Daimon et al. 2002 [Japanese]; El-
bein et al. 2002 [whites from Utah]; Fingerlin et al. 2002
[Finnish]; Rasmussen et al. 2002 [Danish and Swedish];
Horikawa et al. 2003 [Japanese]).
We previously reported that another variant, SNP-44
(designated “CAPN10-g4841TrC”; minor allele fre-
quency 16%), located in intron 3 and 11 bp from SNP-
43, was independently associated with T2DM in whites
from the United Kingdom (Evans et al. 2001). Further
studies have provided tentative support for a role of
SNP-44 in T2DM and related traits: associations with
polycystic ovary syndrome (Gonzalez et al. 2002) and
with measures of oral glucose tolerance (Wang et al.
2002; Tschritter et al. 2003) have been reported. Func-
tional studies suggest that SNP-44 is located in an en-
hancer element and might affect CAPN10 expression
(Horikawa et al. 2000). Also, in the U.K., German, Jap-
anese, and South Indian populations, SNP-44 is in per-
fect linkage disequilibrium ( ) with a missense mu-2r p 1
tation Thr504Ala (SNP-110) and two polymorphisms
in the 5′-UTR (SNP-134 and SNP-135) (Evans et al.
2001; Cassell et al. 2002; Y. Horikawa and P. E.
Schwarz, unpublished data).
To assess the association of SNP-44 with T2DM more
comprehensively, we performed a meta-analysis of all
published SNP-44/T2DM association study data. To
identify all relevant published studies, we searched
PubMed using the keywords “calpain 10,” “diabetes,”
“44,” “SNP 44,” “CAPN10,” and “type 2,” in different
combinations. When necessary, authors were contacted
to obtain exact genotype numbers, so that precise odds
ratios (ORs) from each study could be calculated. Our
search identified 10 published case/control studies, con-
sisting of 3,303 subjects. The studies were spread across
a number of ethnic groups: British (three studies, Evans
et al. 2001); Chinese (Wang et al. 2002); Japanese (Dai-
mon et al. 2002; Horikawa et al. 2003); Finnish/Botnia
(two studies, Orho-Melander et al. 2002); South Indian
(Cassell et al. 2002); and Mexican American (Horikawa
et al. 2000). The frequency of the T2DM-associated
SNP-44 C allele (allele 2) ranged from 6% in Mexican
Americans to 25% in the Botnia I control population.
There was no evidence for OR heterogeneity (Q test
), and, although these studies are only a smallPp .27
sample from the many existing T2DM genetic resources,
a funnel-plot analysis (Egger et al. 1997) suggested an
absence of publication bias ( ). A Mantel-Haen-Pp .44
szel meta-analysis of these studies showed that the C
allele was associated with increased risk of T2DM (OR
1.17 [1.02–1.34], ).Pp .02
Three transmission/disequilibrium tests (TDT) had
been performed (Evans et al. 2001; Cassell et al. 2002;
Orho-Melander et al. 2002). The combined TDT results
demonstrated that the C allele was significantly over-
transmitted (117 transmitted vs. 77 not transmitted,
) from heterozygous parents to diabetic off-Pp .004
spring. Although this result cannot be considered in-
dependent replication, as proband data was included in
the case/control meta-analysis from two of the TDT
studies (Evans et al. 2001; Cassell et al. 2002), it provides
evidence that the association is not due to population
stratification. Of the 10 studies in the meta-analysis, only
1 reported a significant ( ) association (Evans etP ! .05
al. 2001). However, these studies were small and the
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Figure 1 Mantel-Haenszel OR meta-analysis plot (fixed effects) for SNP-44 association with T2DM. Point estimates and 95% CLs for
each previously published, new, and combined case/control study.
mean power to detect an OR of 1.17 at wasP ! .05
∼11% (range 5%–14%).
In the context of genetic association studies, which
test many polymorphisms in numerous candidate genes,
a P value of .02 can only be considered evidence sug-
gestive of a real association. We therefore genotyped
SNP-44 in an additional 4,213 subjects: 3,274 white
European subjects from four case/control studies (one
British, two German, and one Czech); 691 Japanese sub-
jects from two case/control studies; and 248 Mexican
(mestizo) subjects from Mexico City and Orizaba City
from one case/control study. Overall, this provided
2,056 subjects with T2DM and 2,157 controls, and a
power of ∼80% to detect an OR of 1.17. Clinical details
of the study subjects are presented in table 1; further
details are available as supplementary information from
the authors. All studies were approved by the relevant
ethics committee, and all subjects gave their informed
consent.
When all the studies were combined, there was no
evidence for between-studies OR heterogeneity (Q test
); a Mantel-Haenszel fixed-effects model wasPp .23
therefore used for subsequent analysis. Meta-analysis of
the new studies gave an OR for the SNP-44 C allele of
1.18 (1.04–1.34), (fig. 1). A combined meta-Pp .01
analysis of all previously published data and our new
data gave an OR of 1.17 (1.07–1.29), . AllPp .0007
study populations were in Hardy-Weinberg equilibrium
except the T2DM cohort of Horikawa et al. 2003
( ) and the control population of the third Jap-Pp .005
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anese study ( ). Although these deviations mayPp .02
be due to random fluctuation and multiple-hypothesis
testing, they contributed a large amount to heterogeneity
(27% of the Q statistic); excluding these studies, the
SNP-44 C allele OR for the new studies was 1.23 (1.07–
1.40), ; the overall OR was 1.19 (1.08–1.31),Pp .003
. This OR is of similar magnitude to that ofPp .0005
E23K (Gloyn et al. 2003; Love-Gregory et al. 2003;
Nielsen et al. 2003) and Pro12Ala (Altshuler et al. 2000),
the other common variants confirmed as T2DM-suscep-
tibility polymorphisms. An OR of 1.17 is low and may
help explain why there is little evidence for linkage of
the CAPN10 region to T2DM in most populations. The
haplotypes responsible for the CAPN10 linkage seen in
the Mexican American population were associated with
a higher T2DM OR (∼3.0) and were more likely to be
detected by linkage analysis (Horikawa et al. 2000).
These haplotypes are less common in other populations.
SNP-44 is in perfect linkage disequilibrium ( )2r p 1
with the missense mutation, Thr504Ala, and two SNPs
(SNP-134 and SNP-135) in the 5′-UTR and therefore
may not be the causal variant. Further haplotype and
functional analyses are required to confirm which of
these polymorphisms contribute to T2DM susceptibility.
In conclusion, our results have confirmed that a
CAPN10 haplotype defined by the SNP-44 polymor-
phism predisposes to T2DM. Meta-analyses of pub-
lished genetic associations, combined with large repli-
cation studies, are a powerful approach to detecting
susceptibility variants in common disease.
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